Search
Crofelemer
go.drugbank.com/drugs/DB04941ApprovedInvestigationalCrofelemer, previously known as the investigational drug SP-303, is a novel proanthocyanidin purified from the bark latex of the Amazonian Croton tree <i>Croton lechleri</i>. … It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.
Categories: Compounds used in a research, industrial, or household settingStreptococcus pneumoniae type 4 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10322ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 4 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 4 of *Streptococcus pneumoniae*.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Prevenar 13 Suspension For InjectionPrimaquine
go.drugbank.com/drugs/DB01087ApprovedInvestigational(From Martindale, The Extra Pharmacopeia, 30th ed, p404) … It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria.
Categories: Antibiotics for Pneumocystis PneumoniaCelecoxib
go.drugbank.com/drugs/DB00482ApprovedInvestigationalCelecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other … [A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Products: CELECOXIB CAPSULAS POR 100 MG.Human papillomavirus type 31 L1 capsid protein antigen
go.drugbank.com/drugs/DB10310ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 31. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 31 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTIONTelisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigational[L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment … to be approved for this specific patient population.
Magnesium cation
go.drugbank.com/drugs/DB01378ApprovedInvestigationalNutraceuticalWithdrawnWhen taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend … Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn.
Mixtures: MAGVEL 365 MG GRANÜL İÇEREN SAŞE, 10 ADET, MAGVEL 365 MG GRANÜL İÇEREN SAŞE, 20 ADETTrypsin
go.drugbank.com/drugs/DB11237ApprovedInvestigationalVet approvedWhen converted from its zymogen trypsinogen, trypsin is available as an active peptide hydrolase (EC 3.4.21.4) form to cleave peptide chains, mainly at the carboxyl side of the amino acids lysine or arginine … Therapeutic forms of trypsin is obtained from purified extracts of porcine or bovine pancreas and is intended to aid in digestion when administered orally.
Categories: Preparations for Treatment of Wounds and UlcersEflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawn[A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA for the treatment of African trypanosomiasis and hirsutism, respectively, but has since been discontinued … Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis.
Dasabuvir
go.drugbank.com/drugs/DB09183ApprovedApproved in December 2014 by the FDA, Viekira Pak is indicated for the treatment of HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] [FDA Label]. … in combination with [DB09296], [DB09297], and [DB00503] for genotype 1b and with [DB00811] for genotype 1a of Hepatitis C [L852].
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use